glaxosmithkline plc obesity drug wins eu nod for over the counter sales reuters european regulators have cleared the way for glaxosmithkline plc to sell an over the counter version of xenical roche holding ags prescription only drug medicine for obesity glaxos low dose version was approved in february in the u s where it is being launched under the brand name alli the european medicines agency said its experts had recommended granting authorization for glaxos version of orlistat the active ingredient based on the safety and efficacy of roches original product 
